We would like to draw attention of the readership to the problems associated with outcome heterogeneity in clinical trials, with particular reference to anal cancer. Outcome heterogeneity, and the related issue of reporting outcome bias, is a barrier to evidence synthesis [1] [2], particularly in rare diseases where few randomised trials are published. A recent review [3] of trials of chemoradiation for anal squamous cell carcinoma (ASCC) highlights the heterogeneity observed in reporting outcomes and calls for the development of a core set of outcomes.
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This article is protected by copyright. All rights reserved. project [5] has been set up to develop a COS for ASCC using the COMET methodological framework [6] . A primary information gathering phase will be followed by a consensus phase, with patients and health care professionals involved at each stage. An up-to-date systematic review will identify all outcomes used in all trials, observational and qualitative studies published up to January 2016 [5] . This outcomes list will be supplemented by outcomes identified as important to patients through a series of semi-structured patient
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interviews. The complete outcome list will populate an international Delphi process involving patients, health care professionals and trialists. The final COS will be agreed at a consensus meeting in September 2017.
